IL17A and COVID-19: Interestingly, anti-IL-17 treatment with netakimab or secukinumab in patients with severe COVID-19 decreased the incidence of pulmonary embolism, suggesting that IL-17 is a key player contributing to this disease complication40,41 which is in line with the reported pro-coagulant and pro-thrombotic effects of IL-17.42